Rifampicin-dependent antibodies in twice-weekly treated patients.
D000917:Antibody Formation / Q000187:drug effects*; D003298:Coombs Test; D005260:Female; D006801:Humans; D008297:Male; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology
D012293:Rifampin